April 25, 2024

High Blood Pressure Medication Shown To Slow Aging and Extend Lifespan

To date, a caloric limitation diet has actually been considered the most robust anti-aging intervention, promoting longevity throughout types. Research studies of calorie restriction in human beings have actually had side results and mixed outcomes, implying finding medications like rilmenidine that can mimic the benefits of caloric constraint is the most affordable anti-aging method.
For the very first time, we have actually been able to show in animals that rilmenidine can increase life-span. We are now eager to explore if rilmenidine may have other scientific applications.”.
Recommendation: “Rilmenidine extends lifespan and healthspan in Caenorhabditis elegans by means of a nischarin I1-imidazoline receptor” by Dominic F. Bennett, Anita Goyala, Cyril Statzer, Charles W. Beckett, Alexander Tyshkovskiy, Vadim N. Gladyshev, Collin Y. Ewald and João Pedro de Magalhães, 20 January 2023, Aging Cell.DOI: 10.1111/ acel.13774.
This study was carried out by researchers from the University of Liverpool, ETH Zürich, and Harvard Medical School, and moneyed by the Swiss National Science Foundation, LongeCity, and the Biotechnology and Biological Sciences Research Council.

A study recently released in the journal Aging Cell found that administering rilmenidine, a medication utilized to treat high blood pressure, to animals at both young and older ages increases life-span and improves overall health markers, comparable to the effects of calorie constraint.
Researchers have actually found that the high blood pressure drug rilmenidine can extend life-span and slow aging.
New research study findings, published on January 20 in the journal Aging Cell, reveal that animals treated with rilmenidine, presently utilized to deal with high blood pressure (hypertension), at young and older ages increase lifespan and enhance health markers, imitating the results of caloric constraint. Rilmenidine, which is a prescription medication, is marketed under the trademark name Albarel, Hyperium, Iterium, and Tenaxum..
They likewise show that the healthspan and life expectancy advantages of rilmenidine treatment in the roundworm C. elegans are moderated by the I1-imidazoline receptor nish-1, recognizing this receptor as a possible durability target.
Unlike other drugs previously studied for this purpose by the scientists, the widely-prescribed, oral antihypertensive rilmenidine has the capacity for future translatability to human beings as adverse effects are non-severe and unusual.